BRIDGE 53 – Access to innovation
Crossed
Your contact person

Dr. Hinrich Habeck
Managing Director
P +49.40.471 96-400
E-Mail

BRIDGE 53

Infectious diseases remain one of the greatest threats to global health. Innovative approaches to developing new anti-infective agents, which are effective against infections caused by bacteria, viruses, fungi and parasites, are urgently required to meet challenges such as resistance to antibiotics.

Hamburg’s universities and research institutes focus on researching disease mechanisms and new target structures. Industrial partners in North Germany also specialise in the technological validation of novel therapeutic approaches and offer a starting point for promising drug development based on industry standards.

BRIDGE 53 is creating a platform to provide scientists with permanent access to industry partners’ expert knowledge and resources in order to facilitate early access to the potential for discovering and developing drugs. BRIDGE 53’s goal is to stimulate the development of new therapies in the field of infectious diseases.

The Free and Hanseatic City of Hamburg and its port are Germany’s gateway to the world. BRIDGE 53’s name is taken from Hamburg's latitude coordinates (53° 34'31.15 "N) and plays a part in upholding its long, prestigious history of coordinating global perspectives locally.

Funding

BRIDGE 53 is part of the project Hygiene, Infection & Health (HIHeal), which aims to establish a cross-cluster network in the fields of hygiene, infection and health along a common value chain between the Clusters of Gesundheitswirtschaft Hamburg and Life Science Nord.

Please visit our HIHeal Web­seite for further information on HiHeal.

The project is funded by the European Regional Development Fund (ERDF) and the Free and Hanseatic City of Hamburg.